Journal of Thrombosis and Thrombolysis

, Volume 22, Issue 1, pp 71–76 | Cite as

Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy

  • Jessica L. Mega
  • David A. Morrow
  • Christopher P. Cannon
  • Sabina Murphy
  • Richard Cairns
  • Paul M. Ridker
  • Eugene Braunwald
Thrombosis and Neurologic Science

Abstract

Background: While statins have been shown to reduce cerebrovascular events (CVE), the relationship between cholesterol, C-reactive protein (CRP), and CVE in patients treated with different statin strategies is still being explored.

Methods: PROVE IT-TIMI 22 was a randomized trial of intensive (atorvastatin 80 mg/day) and moderate (pravastatin 40 mg/day) statin therapy in 4,162 patients with acute coronary syndromes followed for an average of 24 months; serial biomarkers allowed for an assessment of the lipid and non-lipid effects of statins as they relate to CVE.

Results: In this study, 45 patients on intensive statin therapy and 40 patients on moderate statin therapy had a CVE during the study period (2.1% v. 1.9%, P = 0.62). While the lipid profiles of patients with and without CVE were similar, those with CVE had higher CRP levels at 30 days and 4 months (2.7 v. 1.9, 2.4 v. 1.7 mg/L; P = 0.012, P = 0.005). Day 30 CRP remained an independent predictor of CVE after adjusting for age, development of atrial fibrillation, diabetes, and prior CVE. Patients with low density lipoprotein (LDL) levels < 70 mg/dL and ≥ 70 mg/dL had similar rates of CVE, while patients with CRP < 2 mg/L tended to have lower event rates when compared to those with higher levels. The lowest rates of CVE were seen in patients who had LDL < 70 mg/dL and CRP < 2 mg/L.

Conclusion: In PROVE IT - TIMI 22, achieved LDL levels did not appear to independently impact the rate of CVE. In contrast, patients with elevated CRP levels were at higher risk of stroke or transient ischemic attack, reinforcing the link between inflammation and CVE.

Condensed abstract

The goal of this PROVE IT-TIMI 22 sub-study was to examine the relationship between cholesterol, CRP, and CVE in patients on intensive and moderate statin therapy. The achieved lipid levels were similar in patients with and without a CVE; however, the achieved levels of CRP were higher in patients who subsequently developed a stroke or TIA. These findings further support the relationship between inflammation and CVE.

Keywords

C-reactive protein Cerebrovascular event Cholesterol Hydroxymethylglutaryl-CoA reductase inhibitors 

Abbreviations

CVE

cerebrovascular event

CRP

C-reactive protein

TIA

transient ischemic attack

ACS

acute coronary syndrome

HMG-CoA

3-hydroxy-3-methylglutaryl coenzyme

PROVE IT

Pravastatin or Atorvastatin Evaluation and Infection Therapy

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts (1995) Prospective studies collaboration. Lancet 346:1647–1653Google Scholar
  2. 2.
    Bowman TS, Sesso HD, Ma J, et al (2003) Cholesterol and the risk of ischemic stroke. Stroke 34:2930–2934PubMedCrossRefGoogle Scholar
  3. 3.
    Iso H, Jacobs DR, Jr., Wentworth D, Neaton JD, Cohen JD (1989) Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 320:904–910PubMedCrossRefGoogle Scholar
  4. 4.
    Yano K, Reed DM, MacLean CJ (1989) Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 20:1460–1465PubMedGoogle Scholar
  5. 5.
    Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) (1994) Lancet 344:1383–1389Google Scholar
  6. 6.
    Plehn JF, Davis BR, Sacks FM, et al (1999) Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 99:216–223PubMedGoogle Scholar
  7. 7.
    White HD, Simes RJ, Anderson NE, et al (2000) Pravastatin therapy and the risk of stroke. N Engl J Med 343:317–326PubMedCrossRefGoogle Scholar
  8. 8.
    Byington RP, Davis BR, Plehn JF, et al (2001) Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project. Circulation 103:387–392PubMedGoogle Scholar
  9. 9.
    Waters DD, Schwartz GG, Olsson AG, et al (2002) Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 106:1690–1695PubMedCrossRefGoogle Scholar
  10. 10.
    (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360:7–22Google Scholar
  11. 11.
    Sever PS, Dahlof B, Poulter NR, et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 361:1149–1158PubMedCrossRefGoogle Scholar
  12. 12.
    Collins R, Armitage J, Parish S, Sleight P, Peto R (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363:757–767PubMedCrossRefGoogle Scholar
  13. 13.
    Hebert PR, Gaziano JM, Chan KS, Hennekens CH (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. Jama 278:313–321PubMedCrossRefGoogle Scholar
  14. 14.
    Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG (1997) Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 28:946–950PubMedGoogle Scholar
  15. 15.
    Crouse JR, 3rd, Byington RP, Furberg CD (1998) HMG-CoA reductase inhibitor therapy and stroke risk reduction: An analysis of clinical trials data. Atherosclerosis 138:11–24PubMedCrossRefGoogle Scholar
  16. 16.
    Bucher HC, Griffith LE, Guyatt GH (1998) Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med 128:89–95PubMedGoogle Scholar
  17. 17.
    Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. Bmj 326:1423PubMedCrossRefGoogle Scholar
  18. 18.
    Liao JK (2002) Statins and ischemic stroke. Atheroscler Suppl 3:21–25PubMedCrossRefGoogle Scholar
  19. 19.
    Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100:230–235PubMedGoogle Scholar
  20. 20.
    Albert MA, Danielson E, Rifai N, Ridker PM (2001) Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. Jama 286:64–70PubMedCrossRefGoogle Scholar
  21. 21.
    Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–979PubMedCrossRefGoogle Scholar
  22. 22.
    Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG (2000) C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol 20:1047–1051PubMedGoogle Scholar
  23. 23.
    Ford ES, Giles WH (2000) Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vasc Biol 20:1052–1056Google Scholar
  24. 24.
    Rost NS, Wolf PA, Kase CS, et al (2001) Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 32:2575–2579PubMedGoogle Scholar
  25. 25.
    Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT, Jr., Psaty BM (2004) Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 63:1868–1875PubMedGoogle Scholar
  26. 26.
    Milionis HJ, Rizos E, Goudevenos J, Seferiadis K, Mikhailidis DP, Elisaf MS (2005) Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke 36:1372–1376PubMedCrossRefGoogle Scholar
  27. 27.
    Cannon CP, Braunwald E, McCabe CH, et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504PubMedCrossRefGoogle Scholar
  28. 28.
    Nissen SE, Tuzcu EM, Schoenhagen P, et al (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. Jama 291:1071–1080PubMedCrossRefGoogle Scholar
  29. 29.
    Ridker PM, Cannon CP, Morrow D, et al (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20–28PubMedCrossRefGoogle Scholar
  30. 30.
    Nissen SE, Tuzcu EM, Schoenhagen P, et al (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352:29–38PubMedCrossRefGoogle Scholar
  31. 31.
    Amarenco P, Bogousslavsky J, Callahan AS, et al (2003) Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc Dis 16:389–395PubMedCrossRefGoogle Scholar
  32. 32.
    LaRosa JC, Grundy SM, Waters DD, et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425–1435PubMedCrossRefGoogle Scholar
  33. 33.
    de Lemos JA, Blazing MA, Wiviott SD, et al (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. Jama 292:1307–1316PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2006

Authors and Affiliations

  • Jessica L. Mega
    • 1
    • 2
    • 5
  • David A. Morrow
    • 1
    • 3
  • Christopher P. Cannon
    • 1
    • 3
  • Sabina Murphy
    • 1
  • Richard Cairns
    • 4
  • Paul M. Ridker
    • 3
  • Eugene Braunwald
    • 1
    • 3
  1. 1.TIMI (Thrombolysis in Myocardial Infarction) Study GroupBoston
  2. 2.Cardiovascular Division, Department of MedicineMassachusetts General Hospital and Harvard Medical SchoolBoston
  3. 3.Cardiovascular Division, Department of MedicineBrigham and Women’s Hospital and Harvard Medical SchoolBoston
  4. 4.Nottingham Clinical Research GroupNottinghamEngland
  5. 5.MGH Cardiovascular DivisionBoston

Personalised recommendations